Semaglutide: First Global Approval
The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic®), a modified human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of type 2 diabetes mellitus. It has been developed using Novo Nordisk's proprietary protein-acylation technology, and is administered using an injection device. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight. Once-weekly subcutaneous semaglutide has recently been approved in the US, Puerto Rico and Canada, and has received a positive opinion in the EU for the treatment of patients with type 2 diabetes. It will be launched as the Ozempic® Pen, a pre-filled device. Semaglutide is also under regulatory review in Japan and Switzerland for the treatment of type 2 diabetes. Clinical development for obesity, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease is underway worldwide. This article summarizes the milestones in the development of semaglutide leading to this first approval for type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Semaglutide is a long-acting GLP-1RA agent used once weekly to improve glycemic control in patients with T2DM.115”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [115]
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 10×
“0% of patients at baseline had established CV disease (CVD) [26].”
BackgroundMethodInfluentialDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“Compared with human GLP-1, semaglutide has two amino acid substitutions and is derivatized at lysine 26 with a hydrophilic spacer and a C18 fatty di-acid, which result in increased albumin affinity [4, 9].”
BackgroundSorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495 · cited 3×
“0001) greater improvements from baseline were seen with semaglutide than sitagliptin in other secondary endpoints, including FPG levels, BMI and WC [21].”
BackgroundInfluentialAroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Vilsbøll, T., Bain, S. C., Leiter, L. A., Lingvay, I., Matthews, D., Simó, R., Helmark, I. C., Wijayasinghe, N., & Larsen, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13172 · Cited by 318
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.443 · Cited by 175
Marbury, T. C., Flint, A., Jacobsen, J. B., Derving Karsbøl, J., & Lasseter, K. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0528-2 · Cited by 130
Research works printed but not linked: 5
- Adis Insight. Drug profile: Semaglutide oral—Novo Nordisk. 2017. http://adisinsight.springer.com/drugs/800031465. Accessed 15 Dec 2017.
- Adis Insight. Drug profile: Semaglutide transdermal—Novo Nordisk 2017. http://adisinsight.springer.com/drugs/800050528. Accessed 15 Dec 2017.
- Raun K, Fels JJ, Rosenquist C, et al. Semaglutide, a once-weekly glucagon-like peptide 1 (GLP-1) analog, reduces bodyweight and promotes a more healthy food choice in diet-induced obese rats [abstract no. 1140-P]. Diabetes. 2015;64(Suppl 1):A293.
- Rakipovski G, Rolin B, Kirk R, et al. Long-acting GLP-1 receptor agonists semaglutide and liraglutide protect against development of atherosclerosis in animal models independent of body-weight-lowering effects [abstract no. 244-OR]. Diabetes. 2017;66(Suppl 1):A64.
- Arold G, Kupcova V, Jensen L, et al. Pharmacokinetics and tolerability of semaglutide in subjects with hepatic impairment [abstract no. 822]. Diabetologia. 2017;60(Suppl 1):S380–1.
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Advances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
GPCR drug discovery: new agents, targets and indications
Lorente, J. S., Sokolov, A. V., Ferguson, G., Schiöth, H. B., Hauser, A. S., & Gloriam, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01139-y · Cited by 251
Zhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
Multi-Target Approaches in Metabolic Syndrome
Lillich, F. F., Imig, J. D., & Proschak, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.554961 · Cited by 178
Metadata
- Authors
- Dhillon, S.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Dhillon, Sohita
- Venue
- Drugs
- Published
- 2018-01-23
- Volume
- 78
- Issue
- 2
- Pages
- 275-284
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2786178453
- Cited by
- 104
- References
- 19
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 21 · 2023: 12 · 2022: 7 · 2021: 9 · 2020: 8 · 2019: 9 · 2018: 6
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, GLP-1 receptor agonists, protein acylation, subcutaneous formulation, Ozempic, drug approval, insulin secretion, weight loss, obesity, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease
- MeSH terms
- Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Insulin, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Semaglutide: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-018-0871-0
- The paper
- Dhillon, S. (2018). Semaglutide: First Global Approval. Drugs. https://doi.org/10.1007/s40265-018-0871-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.